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A B S T R A C T
The lung remains an attractive target for the gene therapy of monogenetic diseases such as cystic ﬁbrosis (CF).
Despite over 27 clinical trials, there are still very few gene therapy vectors that have shown any improvement in
lung function; highlighting the need to develop formulations with improved gene transfer potency and the
desirable physiochemical characteristics for eﬃcacious therapy. Herein, we introduce a novel cell penetrating
peptide (CPP)-based non-viral vector that utilises glycosaminoglycan (GAG)-binding enhanced transduction
(GET) for highly eﬃcient gene transfer. GET peptides couple directly with DNA through electrostatic interac-
tions to form nanoparticles (NPs). In order to adapt the GET peptide for eﬃcient in vivo delivery, we engineered
PEGylated versions of the peptide and employed a strategy to form DNA NPs with diﬀerent densities of PEG
coatings. We were able to identify candidate formulations (PEGylation rates≥40%) that shielded the positively
charged surface of particles, maintained colloidal stability in bronchoalveolar lavage ﬂuid (BALF) and retained
gene transfer activity in human bronchial epithelial cell lines and precision cut lung slices (PCLS) in vitro. Using
multiple particle tracking (MPT) technology, we demonstrated that PEG-GET complexes were able to navigate
the mucus mesh and diﬀuse rapidly through patient CF sputum samples ex vivo. When tested in mouse lung
models in vivo, PEGylated particles demonstrated superior biodistribution, improved safety proﬁles and eﬃcient
gene transfer of a reporter luciferase plasmid compared to non-PEGylated complexes. Furthermore, gene ex-
pression was signiﬁcantly enhanced in comparison to polyethylenimine (PEI), a non-viral gene carrier that has
been widely tested in pre-clinical settings. This work describes an innovative approach that combines novel GET
peptides for enhanced transfection with a tuneable PEG coating for eﬃcacious lung gene therapy.
1. Introduction
Cystic ﬁbrosis (CF) is an inherited incurable disease that aﬀects>
70,000 patients globally and is caused by an underlying genetic mu-
tation in the CF transmembrane conductance regulator (CFTR) gene [1].
Although CF is a multisystem disease that aﬀects many organs, about
90% of patient death is due to respiratory failure, making the lungs a
critical target for gene therapy of the disease [2]. Over 1990 diﬀerent
mutations of the CFTR gene have been reported [3]. The majority of
mutations (including the most common F508del aﬀecting 70% of CF
patients) cause the production of defective CFTR proteins that are no
longer able to regulate cyclic adenosine monophosphate (cAMP)-
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dependent chloride secretion, bicarbonate secretion and epithelial so-
dium channels (ENaCs). Eventually this leads to incorrect transport of
ions, mucus stasis/plugging, chronic lung infections and pulmonary
failure [4].
Since the ﬁrst human CF gene therapy trial in 1989, 27 clinical trials
have been carried out by viral (e.g. adenovirus and adeno-associated
virus; AAV) and non-viral (e.g. lipid and cationic polymer) vectors
[5–8]. The majority of viral technologies cannot penetrate mucosal
secretions leading to poor eﬃcacy and/or have safety concerns in-
hibiting their clinical adoption [9]. In 2015, the outcome of the ﬁrst-in-
man phase 2b trial of a non-viral gene therapy for CF using a cationic
liposome-based vector, termed GL67A, was published by the UK Cystic
Fibrosis Gene Therapy Consortium (UKCFGTC) [10]. This was a one
year trial designed to assess clinical eﬃcacy following monthly re-
peated delivery of plasmid (p)DNA/GL67A in 136 patients with CF. The
CFTR gene used in the trial was speciﬁcally engineered to be cytosi-
ne–phosphate–guanidine (CpG) free and contain a human elongation
factor 1 alpha (EF1A1) promoter for reduced inﬂammatory response
and prolonged gene expression, respectively [11]. Inhaling the lipo-
somal vector was safe over a 1 year period and had a marginal bene-
ﬁcial eﬀect on lung function. Despite the limited and variable eﬃcacy,
this was the ﬁrst clinical demonstration showing that repeated admin-
istration of non-viral gene carriers is a feasible and well-tolerated ap-
proach for the treatment of CF.
Developing successful airway gene therapy is complex as gene
transfer agents must penetrate lung mucus and reach the airway epi-
thelium prior to removal from the lung by mucociliary clearance (MCC)
[12]. This navigation is even more challenging in CF lungs due to pa-
thological alteration of mucus properties that makes this barrier even
harder to penetrate [13]. CF sputum is a highly dense meshwork
composed of mucin ﬁbres, possessing negatively charged and hydro-
phobic domains, and other adhesive macromolecules such as DNA
fragments released from bacteria and endogenous cells [14]. As a
consequence, particle diﬀusion is largely impeded within the mucus gel
by steric obstruction and/or mucoadhesive interactions with sputum
components. In particular, conventional non-viral gene vectors for-
mulated with cationic materials possess positively charged surfaces and
thus are readily trapped by negatively charged mucus via electrostatic
interactions [15]. Furthermore, charged particles rapidly aggregate in
physiological ionic environments, leading to entrapment within the
mucus gel via steric obstruction [16]. It has previously been demon-
strated that the modiﬁcation of particle surfaces with a dense layer of
poly(ethylene glycol) (PEG) inhibits particle aggregation as well as
mucoadhesion, thereby leading to eﬃcient mucus penetration of na-
noparticles (NPs) [17, 18]. Importantly, due to their ability to penetrate
airway mucus, PEGylated DNA NPs have been shown to provide
widespread airway distribution, prolonged lung retention and ulti-
mately a high-level transgene expression following inhalation [19–21].
The work presented here is based on novel modiﬁed cell penetrating
peptide (CPP)-based gene vectors. Glycosaminoglycan (GAG)-binding
enhanced transduction (GET) peptides are multi-domain sequences
comprising of a heparan sulfate (HS) cell targeting sequence fused to a
CPP for improved membrane association and synergistically enhanced
intracellular delivery of therapeutic cargoes [22]. We have previously
described GET peptides for improved delivery of a self-reporting cargo
(monomeric red ﬂuorescent protein; mRFP) in diﬃcult-to-transduce
cell types including mesenchymal stem cells (MSCs), human embryonic
stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs).
The GET-system has been utilised for a wide variety of applications
from the spatio-temporal control of cell programming in hydrogel
matrices to the delivery of runt-related transcription factor 2 (RUNX2)
for osteogenesis of MSCs [23, 24]. Furthermore, GET-mRFP proteins
have retained activity when encapsulated into poly(DL-lactic acid-co-
glycolic acid) (PLGA) microparticles for controlled release and sus-
tained delivery to cells over extended periods of time [25].
The initial transfection peptide we generated (P21 LK15 8R; PLR)
was the prototypical example used for nucleotide transfection; med-
iating delivery of DNA- (plasmids) and RNA-based (siRNA, mRNA)
macromolecules into cells [22]. When tested against commercial
transfection reagent Lipofectamine 2000, PLR demonstrated compar-
able transfection eﬃciency albeit requiring a higher DNA dose to pro-
duce the same eﬀect. We also tested other peptide versions containing
diﬀerent HS-binding sequences, one such was derived from ﬁbroblast
growth factor 2 (FGF2) (termed FGF2B) [26]. FGF2B (TYRSRKYTSW-
YVALKR) is a short 16-residue peptide that shows no signiﬁcant cell
penetrating properties by itself, however when coupled to a CPP it
demonstrated up to two orders of magnitude enhanced delivery of re-
combinant proteins into a wide variety of cell types compared to an
unmodiﬁed CPP [22]. Herein we describe GET transfection peptide
FGF2B LK15 8R (FLR) for superior DNA complexation, enhanced gene
delivery and highly eﬃcient transfection of cells in vitro. We prepared
various formulations of PEG DNA NPs, each made-up of diﬀerent molar
ratios of PEGylated to non-PEGylated FLR peptide as a strategy to in-
corporate a controlled density of PEG on the particle surface. We hy-
pothesized that by using this strategy we could engineer PEGylated
complexes with tuneable properties that were stable in biological ﬂuids,
retained enhanced transfection activity and could rapidly penetrate
human CF sputum. Candidate formulations were tested for their ability
to demonstrate eﬃcient, widespread and safe transgene expression in
healthy mouse lung models in vivo.
2. Results and discussion
2.1. DNA NP formation and stability proﬁles
The gene transfer potential of FGF2B had not yet been evaluated. To
test this we designed the FLR peptide, including the amphipathic se-
quence LK15 (L) to improve the DNA condensation ability and in-
tracellular traﬃcking of the peptide [27, 28] along with octa-arginine
(8R) as the CPP (Fig. 1A). Initially, we assessed the DNA complexation
ability of FLR and its components by the YO-PRO-1 assay; a ﬂuores-
cence-based competition assay conventionally used to determine
strength of complexation between DNA and non-viral gene vector ma-
terials via quenching of ﬂuorescence [29, 30]. FLR was capable of
condensing DNA through electrostatic interactions between the posi-
tively charged amines of the peptide and the negatively charged
phosphate groups of the DNA, eliminating the need for complex che-
mical conjugation and deconjugation steps. Complexation was rapid,
with the full eﬀect on ﬂuorescence quenching observed within 30 s. We
compared peptide variants 8R (R), LK15 8R (LR) and FLR (peptide se-
quences shown in Table S1). All the tested peptides demonstrated DNA
condensing activity, however those containing LK15 required the
lowest charge ratio (CR) to achieve complete removal of ﬂuorescence
(Fig. 1B). The LR and FLR peptides were able to complex 98.5 ± 0.1%
and 96.2 ± 0.5% of DNA at CR3, respectively. However the un-
modiﬁed CPP (R alone) was only able to complex 90.3 ± 0.5% of the
DNA at the highest tested CR. The hydrodynamic size and zeta potential
of the DNA NPs were measured in water and 10mM NaCl at pH 7.0,
respectively (Fig. 1C). At CR1 the hydrodynamic size was 267 ± 6 nm
and zeta potential was −24 ± 1mV indicating that there was in-
suﬃcient peptide present to condense the DNA. FLR was able to form
positively charged, small and stable NPs at CR≥ 2. The polydispersity
index (PDI) of the DNA NPs was about 0.2, which indicated relatively
uniform size distribution of the complexes devoid of large aggregates or
sedimentation.
We next explored the possibility of functionalising DNA NPs with
PEG chains. We introduced an N-terminal cysteine to the FLR peptide.
5 kDa PEG maleimide was covalently conjugated to the peptide through
formation of a stable thioether linkage with the thiol group of the cy-
steine residue [31]. We hypothesized that the cationic peptide would
compact the DNA in the centre of the particles and the PEG chains
would orient themselves to form a layer on the particle surface.
G. Osman et al. Journal of Controlled Release 285 (2018) 35–45
36
Thereby, at diﬀerent PEGylation rates we could achieve diﬀerent den-
sities of PEG coatings on the DNA NP surface (Fig. 2A). A blend of
diﬀerent molar ratios of non-PEGylated and PEGylated FLR peptides
were mixed with DNA at CR3 to form particles at diﬀerent PEGylation
rates. To assess the surface characteristics of the DNA complexes, their
hydrodynamic diameter and zeta potential were measured. The sizes of
the DNA NPs at all tested PEGylation rates were between 97 and
107 nm, indicating that inclusion of PEGylated peptides did not un-
dermine the ability of the peptides to condense DNA into compact NPs
(Fig. 2B). DNA complexes formulated with non-PEGylated peptides
exhibited a high positive charge of 21 ± 1mV. The cationic charge
gradually dropped when incrementing fractions of PEGylated peptides
were used, down to a near neutral surface charge observed for DNA
complexes made entirely with PEGylated peptides. This ﬁnding sig-
niﬁes that particle surface shielding can be achieved by precisely con-
trolling the proportions of PEGylated peptides.
Next, we investigated whether PEGylation could shield DNA NPs
from enzymatic digestion of DNA payloads and from particle aggrega-
tion in a physiologically relevant biological ﬂuid. To assess the ability
of FLR peptides to provide eﬃcient protection against nuclease activity,
DNA complexes were incubated with increasing concentrations of nu-
clease (DNase I) and analysed using a gel shift assay. Naked pDNA was
digested by DNase I at all tested concentrations (Fig. 2C). In compar-
ison, DNA NPs made up with non-PEGylated or PEGylated FLR peptides
improved DNA protection following degradative challenge. To in-
vestigate whether PEGylation prevented DNA NPs from aggregation in
a physiologically relevant ﬂuid, we incubated complexes in water or
bronchoalveolar lavage ﬂuid (BALF). BALF, which is collected from
lungs following a lavage procedure with phosphate-buﬀered saline
(PBS), is made up of a mixture of epithelial lining ﬂuid (ELF) and tissue-
speciﬁc cells including immune cells, squamous epithelial cells and
bronchial epithelial cells [32]. Proteomics of BALF has shown that it
contains a dynamic and diverse protein composition that is re-
presentative of pulmonary airways [33]. Following incubation in BALF
for 1 h, the hydrodynamic size of complexes was measured to determine
whether they were able to retain colloidal stability; a physical state in
which particles remain dispersed in a solution at equilibrium. Kineti-
cally unstable particles coagulate and form aggregates. It is estimated
that airway mucus has pore sizes of about 200 nm [34], therefore ag-
gregates or large particles sized beyond this cut-oﬀ are unlikely to
diﬀuse eﬃciently through the airway due to steric hindrance. The size
of DNA NPs in water remained between 93 and 125 nm at all tested
PEGylation rates (Fig. 2D). However, when incubated in BALF com-
plexes of low PEGylation rates exhibited up to a 20-fold increase in
particle diameter. Colloidal stability in BALF was achieved at ≥40%
PEGylation where particle size was between 142 and 167 nm. Im-
portantly, DNA NPs that are able to maintain a diameter of< 200 nm
would have the best chance of navigating the mucus mesh and reaching
Fig. 1. DNA NP formation and characterisation. (A) FLR is a multi-domain peptide made up of a HS GAG binding domain (red), amphiphilic region (blue) and CPP
(purple). When mixed with DNA, FLR peptides form electrostatic interactions with the negatively charged phosphate groups of the plasmid to form nanoparticles
(NPs) through self-assembly. (B) The ability of GET peptides to bind DNA was assessed using a YO-PRO1 ﬂuorescence-based assay. The graph shows a decrease in the
percentage ﬂuorescence as the peptide out competes the dye by complexing DNA at diﬀerent tested (+/−) charge ratios (CRs). (C) Following the formation of DNA
NPs, the physiochemical characteristics of complexes were investigated at diﬀerent CRs. Hydrodynamic size and zeta-potential were measured in ultrapure water and
10mM NaCl at pH 7.0, respectively. Error bars indicate SD, n=3. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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airway epithelium [35].
2.2. Optimized transfection of DNA NPs in vitro
Following successful formation of DNA NPs, the gene transfer po-
tency of the FLR vector was investigated in vitro. In this study, we
compared the transfection eﬃciencies of GET peptides, FLR and PLR, in
NIH3T3 cells via transfection of a reporter pDNA encoding green
ﬂuorescent protein (GFP) [22]. Cells were ﬁxed 24 h post treatment to
allow time for the transient expression of GFP to be captured and the
percentage of transfected cells to be quantiﬁed by ﬂow cytometry. We
observed that the transfection eﬃciency of FLR was enhanced at
CRs≥ 3 where more cationic peptide component was present in the
NPs (Fig. S1). Both FLR and PLR peptides exhibited high transfection
eﬃciency (60.9 ± 5.5% and 29.8 ± 7.8%, respectively). High PLR-
mediated transfection requires higher pDNA dose than FLR as pre-
viously described [22]. LR peptides (lacking a HS targeting domain)
exhibited lower transfection eﬃciency (12.5 ± 2.9%), highlighting the
need for the full multi-functional peptide for superior transfection. The
diﬀerence in transfection eﬃciency observed between GET peptides,
FLR and PLR, is likely due to targeting of diﬀerent cell surface HS-
epitopes. We have previously conﬁrmed that the distinct cell surface
sulfation patterns displayed on the membrane aﬀect the ability of the
diﬀerent HS binding sequence to interact with them [22]. When tested
against a variety of leading commercial transfection reagents including
Lipofectamine 2000 (lipid-based), Lipofectamine 3000 (lipid-based),
JetPEI (polymer-based), TransIT-LT1 and FuGENE HD (both non-lipo-
somal formulations composed of both lipid and protein components),
we found that FLR was comparable to or outperformed the commercial
systems by demonstrating both high eﬃciency (% GFP positive cells)
and low cytotoxicity (Fig. S2).
Our next aim was to test the eﬀect of PEGylation on uptake and
transfection eﬃciency in a human bronchial epithelial cell line
(BEAS2B-R1) using a luciferase reporter gene. PEG shields can greatly
improve colloidal stability however this is often achieved at the expense
of undermining the ability of cationic gene vectors to achieve eﬃcient
gene transfer [36]. This eﬀect is presumably caused by the PEG chains
that sterically hinder the interaction of the membrane-active particle
core with the cell surface. The shielding eﬀect of the PEG corona has
also been reported to sterically inhibit the endosomal release of lipid
and polymer-based gene vectors which are heavily reliant on en-
dosomal escape strategies for high eﬃciency of transfection [37–39].
Conversely, once inside the cell, PEGylation has been shown to improve
the diﬀusion of DNA NPs through the cytoplasm by reducing adhesive
interaction with surrounding bio-components [40]. The PEG chains
may also act to weaken the association between the gene carrier and
DNA. Thereby, improving intracellular de-packaging, release and
bioavailability of the gene [41]. GET peptides utilize HS-GAG binding
ligands to enhance cell surface concentration, membrane association
and in turn improve their translocation across the cellular membrane.
Therefore, candidate PEG peptide formulations must be carefully se-
lected to maintain a balance between their ability to overcome extra-
cellular barriers and retain enhanced intracellular delivery of target
genes. In agreement with previous reports, we found that increasing the
PEGylation rate led to a gradual decrease in DNA uptake and transgene
expression in comparison to non-PEGylated particles (Fig. 3). When
compared to Lipofectamine 2000 and Lipofectamine 3000, we observed
that 0%, 10%, 20% and 40% PEGylated FLR peptides exhibited sig-
niﬁcantly more eﬃcient intracellular uptake. The transfection eﬃ-
ciency of non-PEGylated FLR peptides was comparable to Lipofecta-
mine 2000, however Lipofectamine 3000 demonstrated the highest in
vitro gene transfer. Interestingly, we found that BEAS2B-R1 cells were
Fig. 2. The eﬀect of PEGylation on the physiochemical properties of DNA NPs. (A) Schematic of non-PEGylated and PEGylated FLR peptides blended at diﬀerent
molar ratios to form DNA NPs with a tuneable coating of PEG on the outer surface. We hypothesized that by varying the PEG component we were able to form DNA
NPs at diﬀerent PEGylation rates. For example 20% PEGylation rate would represent a mixture of 20% PEGylated peptide and 80% non-PEGylated peptide. (B) To
conﬁrm the formation of DNA NPs we measured the diameter and charge of complexes at 0%, 10%, 20%, 40%, 60%, 80% and 100% PEGylation rates. The
hydrodynamic size and zeta-potentials were measured in ultrapure water and 10mM NaCl at pH 7.0, respectively. (C) We tested the ability of complexes to protect
DNA from nucleases. Naked pDNA, 0% PEG DNA NPs and 100% PEG DNA NPs were incubated with DNase I for 30min, digested using proteinase K and visualized
using a gel shift assay. Degradation of DNA was evidenced by a shift, smear or loss of the DNA band. (D) Stability of PEGylated DNA complexes was investigated
following 1 h incubation in ultrapure water or 10% (v/v) BALF in PBS. Hydrodynamic diameter of respective NPs was measured by DLS. Error bars indicate SD,
n= 3. Two-tailed Student's t-test, *P < .05, **P < .01.
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exceptionally sensitive to treatment via the commercial transfection
reagents in comparison to NIH3T3 cell lines (Fig. S2B), with both Li-
pofectamine 2000 & 3000 signiﬁcantly eﬀecting cell viability.
Despite demonstrating promising in vitro eﬃciency in lung cell
lines, there are still very few gene therapy vectors that have shown any
improvement in lung function in vivo; highlighting the need to further
evaluate gene transfer in models that retain or mimic native tissue and
cell types. Precision cut lung slices (PCLSs) utilize agarose to stabilise
tissue before sectioning to create a tractable pre-clinically relevant lung
assay which has previously been used for drugs testing and respiratory
disease modelling [42, 43]. In order to examine eﬃciency and toxicity
of gene therapy strategies directly in mouse lung tissues we treated
PCLSs with PEGylated formulations, Lipofectamine 2000 or Lipofecta-
mine 3000 (Fig. S3). We demonstrated that FLR peptides at a
PEGylation rates≥ 40% exhibited enhanced gene transfer of a reporter
luciferase plasmid in comparison to the lipid-based commercial trans-
fection reagents (with very poor eﬃciencies; 29 ± 14 RLU/mg and
24 ± 17 RLU/mg for Lipofectamine 2000 and 3000, respectively). In
addition, we have shown that FLR peptides did not negatively aﬀect the
viability of tissues at any of the tested PEGylation rates. To this end,
DNA NPs for in vivo applications should be determined based both on
colloidal stability in a relevant physiological environment and ability to
transfect cells. DNA NPs formulated with an inclusion of 40% PEGy-
lated peptide were thus selected as good candidates for subsequent
studies as they demonstrated the highest in vitro transfection activity
among formulations and retained an acceptable colloidal stability in
BALF (Fig. 2D).
2.3. Ex vivo NP tracking in human CF sputum samples
Next, we compared the ex vivo diﬀusion of 0%, 40% and 60%
PEGylated particles through sputum samples freshly collected from CF
patients. We compared 40% with 60% as examples of PEGylation
quantities around the threshold at which transfection eﬃciency was
aﬀected. TEM images of PEGylated DNA complexes were suggestive of
the formation of spherical compact particles (Fig. 4A). NP dimensions
were in agreement with hydrodynamic size measurements. Multiple
particle tracking (MTP) technology was used to analyze the diﬀusion of
cyanine3 (Cy3) and/or cyanine5 (Cy5)-labelled DNA NPs [44]. The
mean squared displacement (MSD) is a square of distance travelled by
an individual particle at a given time interval (i.e. time scale), and thus
the MSD is directly proportional to particle diﬀusion rates [9]. The
representative trajectories of the tested formulations demonstrated that
particles lacking the PEG component exhibited constrained movement
in CF mucus in comparison to greater distances travelled by 40% and
60% PEG DNA NPs (Fig. 4B–C).
It has been reported that inhaled particles are cleared rapidly from
the mucus of CF patients within the ﬁrst hour [45]. Here, we deﬁned
particles capable of diﬀusing through sputum with MSD≥ 1 μm2 at a
time scale of 1 s as “mucus penetrating” based on their diﬀusive tra-
jectories; these particles are likely to have greater chances of reaching
the epithelium covered by the airway mucus gel layer prior to being
cleared from the lung via MCC. On average, median MSD values were
greater for PEGylated DNA NPs compared to their non-PEGylated
counterpart; however, the diﬀerences were not statistically signiﬁcant
presumably due to the highly heterogeneous nature of CF sputum
(Fig. 4D). Nonetheless, ~30% of PEGylated DNA NPs (of 40% or 60%
PEG) were categorized as mucus penetrating fractions, which is 6-fold
greater than the fraction observed with non-PEGylated particles (i.e.
~5%), reaching statistically signiﬁcant diﬀerences (Fig. 4E).
2.4. In vivo gene delivery in healthy mouse lung models
It is thought that successful treatment of lung diseases such as CF
can be achieved by even low transgene expression in minimal numbers
of cells (≤ 10% of cells) [46, 47]. We expected that PEGylated for-
mulations with improved stability-proﬁles and mucus penetrating
properties would provide more widespread gene delivery in the airways
and alveolar region (parenchyma) compared to non-PEGylated particles
in vivo. Although mucus is not abundant in the lung parenchyma,
pulmonary surfactants produced by type II alveolar epithelial cells have
similarly been shown to readily interact with naked cationic gene
vectors resulting in de-stabilization and aggregation of DNA-gene car-
rier complexes [48, 49]. As 40% PEGylated NPs retain both transfection
eﬃciency in vitro and stability ex vivo we compared this to non-PE-
Gylated NPs by aerosolizing them into mouse lungs. To visualize the
distribution of 0% and 40% PEGylated complexes in mouse lung models
in vivo, DNA NPs containing Cy5-labelled DNA were intratracheally
administered by an aerosol-generating microsprayer to the lungs of
6–8week female BALB/c mice. Thirty minutes following
Fig. 3. In vitro uptake and transfection eﬃciency of DNA NPs at diﬀerent
PEGylation rates. (A) Human bronchial epithelial cells (BEAS2B-R1) cells were
treated with rhodamine-labelled DNA complexes for 4 h, trypsinized to remove
any extracellularly bound DNA and ﬂuorescence intensity was measured using
ﬂow cytometry. (B–C) For the transgene expression study, BEAS2B-R1 cells
were transfected for 24 h with 1 μg of a reporter gene expressing luciferase. (B)
Transfection eﬃciency and (C) cell viability (PrestoBlue assay) were assessed at
a 48 h time-point. Error bars indicate SD, n=6. One-way ANOVA with
Bonferroni's post-test or one-way ANOVA with Dunnett's test for the compar-
ison of each treatment group with the control (for cell viability), *P < .05,
**P < .01.
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administration, lungs were harvested and analysed by ﬂuorescence
microscopy. Non-PEGylated DNA NPs appeared to be sparsely dis-
tributed in the lumen, in contrast to the widespread and more uniform
distribution observed with 40% PEG DNA NPs (Fig. 5A). Image-based
quantiﬁcation of ﬂuorescence conﬁrmed that PEGylated particles ex-
hibited signiﬁcantly greater coverage in both large airways (Fig. 5B)
and the lung parenchyma (Fig. 5C).
Next, we sought to determine whether improved lung distribution
by PEGylation translated to enhanced gene transfer in vivo of a luci-
ferase-expressing plasmid. Luciferase is not a cell autonomous reporter
and as such does not allow the quantiﬁcation of the percentage of
transfected cells. However Luciferase bioluminescence allows non-in-
vasive quantitative transgene expression to be measured directly. Each
mouse was treated with 10 μg of DNA carried by diﬀerent delivery
systems, including non-PEGylated FLR peptides, PEGylated FLR pep-
tides or polyethylenimine (PEI). PEI is a non-viral polymer-based gene
vector that has been widely explored for preclinical lung gene therapy
studies [50] but previously been shown to be unable to eﬃciently pe-
netrate CF sputum [19] similar to our observation with the non-PE-
Gylated peptide in this study (Fig. 4). Mice treated with 40% PEG DNA
complexes demonstrated signiﬁcantly superior transgene expression
compared to non-PEGylated DNA NPs and PEI DNA NPs (Fig. 6A).
Despite their high in vitro transfection eﬃciency, DNA NPs based on
non-PEGylated peptides failed to provide signiﬁcantly improved in vivo
gene transfer eﬃcacy compared to the DNA only control, underscoring
the importance of testing gene vectors in relevant in vivo conditions.
Following inhalation, gene vectors can be rapidly cleared by al-
veolar macrophages directly via opsonin-independent scavenger re-
ceptors or by opsonin-dependent mechanisms. Other immune cells,
including neutrophils, are also recruited as part of the innate immune
response. Opsonins (proteins present in serum) are adsorbed onto the
surface of foreign particles [51]. Alveolar macrophages can easily re-
cognize, engulf and destroy opsonized DNA NPs as well as triggering
lung epithelial cell-mediated production of pro-inﬂammatory cytokines
[52]. Pro-inﬂammatory cytokines, such as TNF-α and IL-1β, initiate the
production of further inﬂammatory mediators which can eventually
cause acute lung toxicity by disrupting pulmonary endothelial cells and
compromising epithelial integrity [53]. It is well documented that
PEGylation can help improve the safety proﬁle of DNA NPs [54, 55].
The ﬂexible hydrophilic PEG chains sterically shield the active particle
core, making it thermodynamically unfavourable for adsorption of
proteins and reducing their uptake by surrounding immune cells [56].
In addition, alveolar macrophages show increased phagocytic uptake of
particles> 250 nm [57]. Thereby, PEGylated DNA NPs that show su-
perior colloidal stability (with lower aggregation) are less susceptible to
rapid macrophage phagocytosis [58].
The acute toxicity of the diﬀerent gene vectors was assessed after a
single administration by analysis of cell counts from BALF samples
collected 24 h post administration (Fig. 6B). Cell counts give an in-
dication of immune cell inﬁltration; a higher number of cells in the
collected BALF indicates an increased host immune response. In par-
allel, histological analysis was conducted for microscopic observation of
immune cell inﬁltration induced by the inhaled gene vectors (Fig. 6D).
Although not signiﬁcant, we observed an increase in the percentage of
neutrophils in the BALF of mice that inhaled non-PEGylated and PE-
Gylated DNA NP formulations (16 ± 4% and 15 ± 4%, respectively)
compared to water (7 ± 6%) (Fig. 6C). In addition, we found that non-
PEGylated complexes exhibited elevated neutrophil inﬁltration com-
pared to the mice treated with water (control) (Fig. 6E). All lung gene
vectors trigger a level of innate immune response due to the introduc-
tion of foreign particles [59], so we went on to further interrogate the
safety proﬁle of the gene carriers by quantitative analysis of pro-in-
ﬂammatory cytokine levels in BALF. Both 0% PEG DNA NPs and 40%
PEG DNA NPs exhibited statistically signiﬁcant but marginal increase in
the levels of TNF-α and IL-1β (Fig. S4) compared to water-treated
controls. Interestingly we did not observe an extra anti-inﬂammatory
eﬀect by the incorporation of PEG corona on the complexes. Peptide-
based systems have negligible inﬂammatory eﬀect, in comparison to
cationic-polymer and lipid-based systems; which we demonstrate for
the GET peptide system. Many factors can impact the potential im-
munogenic properties of PEG coatings including dosage, PEG molecular
weight and PEG surface density [54]. Taken collectively, these data
show that both PEGylated and non-PEGylated DNA NPs appear to elicit
a very minimal inﬂammatory response following a single dose admin-
istration to healthy mouse lungs which is a property intrinsic to many
peptide-based systems.
Fig. 4. Multiple particle tracking of DNA NPs in ex vivo human CF sputum samples. The diﬀusion of DNA NPs at 0%, 40% and 60% PEGylation rates was investigated
in freshly expectorated patient CF sputum samples. (A) Representative transmission electron micrographs of the respective NPs. Scale bar, 500 nm on original images
and 250 nm on inserts. Following a 1 h incubation in sputum, movies of NP displacement were captured and analysed by MPT technology. (B) Representative
trajectories of particles moving through CF sputum and (C) mean squared displacement (MSD) of particles. Dot plots of (D) ensemble-median MSD and (E) percentage
mucus penetrating particles (MSD≥ 1 μm2). Error bars indicate SD, n=5–6 patient samples (> 100 DNA NPs tracked for each experiment). One-way ANOVA with
Bonferroni's post-tests; *P < .05, ** P < .01.
Fig. 5. In vivo bio-distribution of PEGylated DNA
complexes in healthy mouse lung models. Lung tis-
sues were harvested 30min following intratracheal
administration of Cy5-labelled DNA NPs at 0% and
40% PEGylation rates. (A) Representative images of
NP distribution in large airways and lung par-
enchyma following administration of the respective
NPs (red). Scale bar, 0.2 mm. Cell nuclei were
stained with DAPI (blue). Image-based quantiﬁca-
tion of (B) coverage of NPs in large airways and (C)
distribution of NPs in the lung parenchyma. Error
bars indicate SD, n= 3 mice/group (> 30 sections
were analysed per mouse). Two-tailed Student's t-
test, *P < .05, **P < .01. (For interpretation of the
references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
G. Osman et al. Journal of Controlled Release 285 (2018) 35–45
41
3. Conclusions
In recent years, overcoming the airway mucus barrier has been
identiﬁed as one of the greatest challenges to successful respiratory
gene therapy [16, 60]. Non-viral vectors can easily be modiﬁed to
target speciﬁc cell-surface ligands, navigate extracellular barriers and
improve intracellular traﬃcking of genetic cargo. Despite showing
promise, the low transfection eﬃcacy of non-viral vectors compared to
viral gene carriers has limited their adoption. Importantly, GET-pep-
tides (i.e. CPPs that have been modiﬁed for highly eﬃcient intracellular
uptake) have the potential to overcome challenges in insuﬃcient gene
transfer of non-viral vectors that have thus far inhibited their clinical
application. In this study we have described a strategy for optimizing
GET peptide vectors with an adaptable PEG coating to formulate DNA
NPs with the desired characteristics for eﬃcacious lung gene therapy. A
critical challenge for modifying GET-technology for in vivo lung ap-
plications was the balance between overcoming extracellular barriers
without functionally masking the active peptide core which is required
for GET-mediated enhanced cellular uptake. The conformational
freedom aﬀorded by ﬂexible PEG chains and precisely tuning the
density of PEG coating allowed for the selection of candidate for-
mulations with desirable physiochemical properties. In addition, by
using this method we were able to eliminate the need for employing a
de-conjugation strategy for removal of PEG at the target site which
often adds complexity to formulation and delivery processes. PEGylated
particles were capable of maintaining colloidal stability in biological
ﬂuids and navigating eﬃciently through human CF sputum samples.
When tested in mouse lung models in vivo these particles demonstrated
superior lung distribution and transgene expression compared to the
non-PEGylated version while retaining good safety proﬁles. Collectively
these results show that GET peptides demonstrate signiﬁcant potential
for in vitro and in vivo gene transfer. Furthermore, PEG-GET tech-
nology could facilitate new approaches for overcoming biological bar-
riers for the successful gene therapy of muco-obstructive lung diseases
such as CF, asthma and chronic obstructive pulmonary disease (COPD).
4. Experimental section
4.1. Peptide synthesis
Peptides were synthesised using solid phase tert-butyloxycarbonyl
(t-Boc) chemistry and puriﬁed to be>90% by Protein Peptide
Research Ltd. (PPR, UK). Peptide sequences are shown in Table S1. For
the synthesis of PEGylated peptides, 5 kDa PEG chains were conjugated
to FLR through a maleimide-thiol coupling reaction (PPR, UK). PEG
maleimide was reacted with the thiol group of the terminal cysteine
residue of the peptide. The PEG to peptide bond was formed through
formation of a stable thioether linkage.
4.2. Preparation of DNA
For in vitro transfection, a Gaussia luciferase (GLuc) reporter
plasmid (pCMV-Gluc2) containing a cytomegalovirus (CMV) promotor
was employed (New England Biolabs). For multiple particle tracking
and in vivo gene delivery, a ﬁreﬂy luciferase-expressing plasmid driven
by a CMV promoter and ﬂuorescently labelled versions of the plasmid
DNA with Cyanine3 (Cy3) or Cyanine5 (Cy5) were prepared as pre-
viously described [21, 61]. Plasmid purity was conﬁrmed using the
NanoDrop 1000 spectrophotometer (ThermoFisher).
4.3. YO-PRO-1 assay for assessing DNA complexation
The optimal DNA binding ratio of peptide to DNA was determined
using the YO-PRO-1 ﬂuorescence-based assay. 10 μg DNA was diluted
in 60 μL 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-
buﬀered saline (10mM HEPES, 150mM sodium chloride (NaCl) solu-
tion, pH 7.4). 1 mM YO-PRO-1 stock solution was diluted to 0.1mM in
dimethyl sulfoxide (DMSO). 2.7 μL of 0.1mM YO-PRO-1 solution was
Fig. 6. Transgene expression and safety proﬁle of DNA NPs. (A) In vivo mouse lung transgene expression of luciferase activity following intratracheal administration
of PEGylated DNA NPs. Acute toxicity of the complexes was assessed by (B) cell counts and (C) percentage of macrophages and neutrophils from BALF of treated
lungs 24 h post administration. (D) Representative images of lung sections stained with haematoxylin and eosin. AW, airway, arrow indicates cellular inﬁltrate. Scale
bar, 100 μm. (E) Histopathological scoring of lung inﬂammation. Error bars indicate SD, n=8–9 mice/group for transgene expression and cell counts, n= 5 mice/
group for histopathological scoring. One-way ANOVA with Bonferroni's post-tests; *P < .05, **P < .01.
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made up to 60 μL in HEPES-buﬀered saline and added dropwise to the
diluted DNA. The DNA/YO-PRO-1 solution was mixed, wrapped in foil
and incubated for 5 h at room temperature (RT). Following incubation,
the DNA/YO-PRO-1 solution was made up to 1mL in HEPES-buﬀered
saline and 100 μL aliquots were pipetted into Eppendorf tubes per
treatment condition. Peptide amounts corresponding to the desired
(+/−) charge ratios (CRs) were added to each Eppendorf. Peptide/
DNA/YO-PRO-1 solutions were mixed and incubated at RT for 10min.
Fluorescence measurements were analysed using the TECAN inﬁnite
200PRO multimode reader. Similarly, a no DNA control was made by
diluting 2.7 μL of the diluted YO-PRO-1 solution in 120 μL HEPES-
buﬀered saline and following the procedure above.
4.4. Formation of DNA NPs
DNA NPs were formulated by the dropwise addition of DNA (0.1 μg/
μL) to a volume of swirling 1mM peptide solution. The peptide solution
was a mixture of non-PEGylated and PEGylated peptide at 0%, 10%,
20%, 40%, 60%, 80% and 100% PEGylation rates. PEGylation rate was
deﬁned as the molar ratio of PEGylated to non-PEGylated peptide.
Following the addition of DNA to peptide, the complexes were in-
cubated for 30min at RT. Polyethylenimine (PEI) NPs were made
freshly as previously described [21]. NPs were washed three times with
ultrapure distilled water and re-concentrated to 0.2 μg/μL using Amicon
Ultra Centrifugal Filters (100,000 molecular weight cut-oﬀ; Millipore).
4.5. Dynamic light scattering (DLS) and zeta potential measurements
Hydrodynamic diameter of DNA NPs was determined in water by
dynamic light scattering (DLS) and assessed in disposable low volume
cuvettes. Zeta potential was measured in 10mM NaCl at pH 7.0 by laser
Doppler anemometry. NPs were measured by DLS following 1 h in-
cubation in ultrapure water or 10% (v/v) bronchoalveolar lavage ﬂuid
(BALF) in phosphate buﬀered saline (PBS). Measurements of hydro-
dynamic size and zeta-potential were performed at RT using Zetasizer
Nano ZS90 apparatus (Malvern Instruments). For each sample, 3 mea-
surements were taken and each measurement was set to 10 runs.
4.6. DNase protection assay
Nuclease stability of DNA NPs was investigated following their in-
cubation for 30min at 37 °C in the presence of diﬀerent concentrations
of DNase I. DNase I buﬀer was made-up at 0.025 U/μL, 0.0025 U/μL
and 0.00025 U/μL as described in the manufacturers guide (RNase-Free
DNase, Qiagen). Following DNase treatment, complexes and naked
pDNA were treated with proteinase K (20 μg) to remove peptide and
allow visualisation of DNA by a gel sift assay. Samples were run on a 1%
agarose gel (with 0.5 μg/mL ethidium bromide (EtBr)) in 1× tris-
acetate-ethylenediaminetetraacetic acid (EDTA) (TAE) buﬀer and vi-
sualized on a Luminescent Image Analyser LAS-4000 (FUJIFILM).
4.7. Cell culture of BEAS2B-R1 cells
BEAS2B-R1 human bronchial epithelial cells were maintained in
growth media (GM) containing Dulbecco's modiﬁed Eagle's medium
(DMEM) with 10% (v/v) fetal calf serum (FCS) supplemented with
2mM L-glutamine and 100 μg/mL streptomycin. All cells were in-
cubated at 37 °C under humidiﬁed 5% carbon dioxide (CO2) conditions,
grown in T-75 culture ﬂasks and passaged (with a standard trypsini-
zation protocol using 0.25% (w/v) trypsin/2mM EDTA solution) every
2–3 days or when they reached 80% conﬂuency.
4.8. Cellular uptake of ﬂuorescently-labelled DNA NPs
Cells were seeded at 4×104 cells/well in 24 well plates and in-
cubated overnight in 500 μL of GM. For each well of cells to be treated,
1 μg rhodamine-labelled DNA was diluted in 25 μL Opti-MEM and
mixed. Peptide in 25 μL Opti-MEM was added to the diluted DNA at
CR3. The solution was mixed and incubated for 20min at RT to allow
complexation of the peptide to the DNA. The cells were aspirated,
washed with PBS and replaced with 200 μL GM. Each well of cells was
treated with 50 μL of peptide/DNA complex solution and incubated.
Following a 4 h treatment, cells were treated with 25% (w/v) trypsin/
2mM EDTA and ﬁxed in 3.7% (w/v) paraformaldehyde (PFA) in pre-
paration for ﬂow cytometry. Rhodamine-labelled cells were analysed
on a Beckman Coulter Astrios EQ Cell Sorter using a green 561 nm laser
(40,000 cells; gated on untreated cells by forward/side scatter). Data
was analysed on ﬂow cytometry analysis software (WEASEL) and mean
ﬂuorescence intensity was used for statistical analysis.
4.9. In vitro transfection of a luciferase reporter gene
Cells were seeded at 4×104 cells/well in 24 well plates and in-
cubated overnight in 500 μL of GM. For each well of cells to be trans-
fected, 1 μg DNA was diluted in 25 μL Opti-MEM and mixed. Peptide in
25 μL Opti-MEM was added to the diluted DNA at CR3. The solution
was mixed and incubated for 20min at RT to allow complexation of the
peptide to the DNA. The wells were aspirated, washed with PBS and
replaced with 200 μL GM. Each well of cells was treated with 50 μL of
peptide/DNA complex solution. Following treatment, cells were in-
cubated for 48 h at 37 °C under humidiﬁed 5% CO2 conditions. GLuc
expression was analysed as described in BioLux GLuc Assay Kit (New
England Biolabs) and luminescence was measured in duplicate using a
TECAN inﬁnite 200PRO multimode reader.
The toxicity of gene carriers was assessed 48 h post-transfection by a
PrestoBlue metabolic activity assay (Invitrogen). 10× solution of
PrestoBlue reagent was diluted to a 1× solution in Hanks' balanced salt
solution (HBSS). Cells cultured on 24 well plates were aspirated and
washed with PBS. 250 μL 1× PrestoBlue reagent solution was added to
each well, the plate was covered in foil (PrestoBlue assay is a light
sensitive assay) and incubated at 37 °C for 15min. Following incuba-
tion, 100 μL of PrestoBlue solution was transferred to a black 96 well
plate. Fluorescence intensity was measured in duplicate using a TECAN
inﬁnite 200PRO multimode reader at excitation/emission 560 nm/
590 nm. Relative ﬂuorescence units (RFU) values of treated cells were
divided by the ﬂuorescence values of untreated cells for percentage cell
viability.
4.10. Transmission electron microscopy (TEM)
DNA NPs were imaged using TEM to determine their morphology.
The complexes were prepared as described above and diluted to 0.1 μg/
μL in ultrapure water. A drop of the sample was cast onto a TEM grid
and air-dried at RT for several hours before examination. The TEM
(H7600; Hitachi High Technologies America, Johns Hopkins University
USA) was operated at 80 kV and 3–5 images were taken per grid.
4.11. Multiple particle tracking
The diﬀusion of Cy3 and Cy5-labelled DNA NPs were tracked in
freshly expectorated CF mucus of patients from Johns Hopkins Cystic
Fibrosis Centre as previously described [9]. CF sputum samples were
collected after receiving written informed consent and approval from
the Johns Hopkins Institutional Review Board (study NA_00046768).
There were no speciﬁc exclusion criteria for patients based on their
clinical status. However, patient samples could be excluded based on
quality (i.e. noticeable amounts of saliva contamination).
A blend of non-PEGylated and PEGylated FLR peptides were com-
plexed with Cy3 or Cy5-labelled DNA (DNA concentration 0.5 μg/μL).
0.75 μL of ﬂuorescently labelled complexes were added to 30 μL of a CF
sputum sample and mixed. Sputum aliquots were used on the day of
collection and kept sealed to prevent dehydration of the sample.
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Following a 1 h incubation at RT, 20 s movies of NP displacement were
captured using an inverted epiﬂuorescence microscope (Axio Observer;
Zeiss). NP trajectories were analysed using multiple particle tracking
(MTP) software based on a previously developed algorithm [44]. The
algorithm was written on Matrix Laboratory (MATLAB) software and
used to calculate the time-averaged mean squared displacement (MSD)
of particles through the sputum. Particles were distinguished from
background by ﬂuorescence intensity, size, and eccentricity parameters,
as previously demonstrated, and their trajectories were retrieved by
monitoring x- and y-coordinates of complexes over time (i.e. frame). NP
trajectories were then analysed using MTP software based on a pre-
viously developed algorithm which was used to calculate the ensemble-
median MSD of particles moving through the sputum [44]. For each
sputum sample, 3–5 videos were collected.
5. Animal studies
Animal studies were carried out on 6–8week female BALB/c mice as
previously described [21] in accordance with Johns Hopkins University
Animal Care and Use Committee guidelines.
Mice were anesthetized with an intraperitoneal (i.p.) injection of
2,2,2-tribromoethanol working solution (Sigma Aldrich). 50 μL FLR
peptide/DNA NPs (DNA concentration 0.2 μg/μL) were administered by
intratracheal microspray (Penn-Century). For bio-distribution studies,
mice were treated with Cy3-labelled DNA NPs. Thirty min post ad-
ministration, lungs were harvested and ﬂash frozen in Optimal Cutting
Temperature (OCT) compound (Fisher Healthcare). To determine bio-
distribution, lung slices were cryosectioned (CM1950 cryostat, Leica
Biosystems) and stained with 4′,6-diamidino-2-phenylindole (DAPI).
Images were taken on Carl Zeiss LSM-710 confocal microscope and
quantiﬁed using ImageJ software (> 30 sections were analysed per
mouse).
For transgene expression studies, mice were treated with luciferase
expressing reporter plasmid driven by CMV promotor. 48 h post ad-
ministration lungs were harvested and homogenised. The luciferase
activity was measured using a luciferase assay kit (Thermo Scientiﬁc
Pierce). Brieﬂy, samples were freeze thawed 3 times in the presence of
1× reporter lysis buﬀer and centrifuged (10,000×g, 10min). 20 μL of
supernatant was mixed with the luciferase substrate and relative light
units (RLU) were immediately measured on 20/20n luminometer.
Bicinchoninic acid (BCA) Protein Assay Kit (Thermo Scientiﬁc Pierce)
was used to normalise luciferase activity.
For the safety study, mice were treated with 0% or 40% PEGylated
DNA NPs. 24 h post administration lungs were washed with 2.5mL PBS
× 3 to collect BALF for total cell counts and diﬀerential cell counts
(Diﬀerential Quick Stain Kit, Modiﬁed Giemsa). Alternatively, lungs
were ﬁxed in paraﬃn, sectioned (CM1950 cryostat, Leica Biosystems)
and stained with haematoxylin and eosin. Inﬂammatory scores were
calculated by enumerating neutrophil inﬁltration, as previously de-
scribed [62, 63]. Morphometric analysis was carried out double-blind
in 10 random ﬁelds of view per slide and then summed (≥ 5 slides per
mouse). Tissue slices were imaged on Carl Zeiss LSM-710 confocal
microscope.
6. Statistical analysis
For in vitro transfection and uptake, data were compiled from six
individual experiments (n=6). The number of experiments (n) refers
to experiments carried out on cells at diﬀerent numbers of cell culture
passages. For MPT experiments, median and SD were compiled from
human CF patient mucus samples. Due to the heterogeneity of sputum
samples, particles were tracked in n=5/6 patient samples (3–5 videos/
sample,> 100 DNA NPs tracked/sample). For in vivo biodistribution
and transgene expression experiments, data were compiled from n=3
(> 30 sections/mouse) and n=8–9 mice/group, respectively. For total
cell counts and diﬀerential cell counts in BALF, data were compiled
from n=8 and n=5 (>4 slides/mouse, > 100 cells were counted/
slide) mice/group, respectively. For histopathological scores, data were
compiled from n=5 mice/group (≥ 5 slides/mouse, 10 random ﬁelds
of view/slide). Data were presented as mean ± SD and analysed by
Prism statistical analysis software (GraphPad). Statistical signiﬁcance
was measured between two groups using a two-tailed Student's t-test for
comparison, between multiple groups by analysis of variance (ANOVA)
with Bonferroni's multiple comparison test for post-hoc analysis or
using ANOVA with Dunnett's test for the comparison of each treatment
group with the control (for cell viability).
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